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ORIGINAL ARTICLE
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Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is the most specific marker of  prodromal alpha-synucleinopathies. We sought to 
delineate the baseline clinical characteristics of  RBD and evaluate risk stratification models.
Methods: Clinical assessments were performed in 171 RBD, 296 control, and 119 untreated Parkinson’s (PD) participants. Putative risk measures were 
assessed as predictors of  prodromal neurodegeneration, and Movement Disorders Society (MDS) criteria for prodromal PD were applied. Participants were 
screened for common leucine-rich repeat kinase 2 (LRRK2)/glucocerebrosidase gene (GBA) gene mutations.
Results: Compared to controls, participants with RBD had higher rates of  solvent exposure, head injury, smoking, obesity, and antidepressant use. GBA 
mutations were more common in RBD, but no LRRK2 mutations were found. RBD participants performed significantly worse than controls on Unified Parkinson’s 
Disease Rating Scale (UPDRS)-III, timed “get-up-and-go”, Flamingo test, Sniffin Sticks, and cognitive tests and had worse measures of  constipation, quality 
of  life (QOL), and orthostatic hypotension. For all these measures except UPDRS-III, RBD and PD participants were equally impaired. Depression, anxiety, 
and apathy were worse in RBD compared to PD participants. Stratification of  people with RBD according to antidepressant use, obesity, and age altered the 
odds ratio (OR) of  hyposmia compared to controls from 3.4 to 45.5. 74% (95% confidence interval [CI] 66%, 80%) of  RBD participants met the MDS criteria for 
probable prodromal Parkinson’s compared to 0.3% (95% CI 0.009%, 2%) of  controls.
Conclusions: People with RBD are impaired across a range of  clinical measures consistent with prodromal PD and suggestive of  a more severe nonmotor 
subtype. Clinical risk stratification has the potential to select higher risk patients for neuroprotective interventions.
Keywords: RBD, Prodromal, Neurodegeneration, Parkinson’s Disease.
INTRODUCTION
Emerging evidence over the past 15 years has established rapid 
eye movement (REM) sleep behavior disorder (RBD) as a 
highly specific marker of the prodromal phase of alpha-synu-
cleinopathies, in particular Parkinson’s disease (PD), dementia 
with Lewy bodies (DLB), and multiple system atrophy (MSA).1 
This parasomnia, characterized by the loss of normal muscle 
atonia during REM sleep, is associated with a future risk of 
neurodegenerative disease reaching more than 80% in some 
studies.2 There is, however, considerable variation in these 
conversion rates among different cohorts worldwide, and even 
within cohorts, the latency to onset of a defined neurodegener-
ative disorder is highly variable.3–5
Accurate identification of those patients at highest risk of 
imminent phenoconversion would facilitate recruitment to tri-
als of neuroprotective agents aimed at delaying the onset of 
alpha-synucleinopathies.6 Given the large numbers of patients 
needed for such trials, risk stratification methods must be 
standardized and reproducible across different geographical 
regions. One method of risk stratification recently proposed by 
Berg et al.7 is the Movement Disorder Society (MDS) Criteria 
for Prodromal PD.7 This method takes the likelihood ratios for 
future PD conferred by a number of background risk factors 
and early neurodegenerative signs and combines them into a 
probability score, with a suggested threshold of 80% indicating 
probable prodromal PD. Application of these criteria in popu-
lation and prodromal cohorts has yielded promising results,8,9 
but they require further validation in prospective cohort studies.
Part of the variation in latency from RBD diagnosis to conver-
sion may be a result of differences in the time at which patients 
present to sleep services, such that patients presenting later may 
be at a more advanced prodromal stage. We sought to explore 
the effect of common comorbidities that may influence this. 
One such comorbidity is depression because the use of anti-
depressants can exacerbate RBD symptoms and may therefore 
unmask the condition at an earlier stage.10 Respiratory sleep 
disorders may conceivably exert a similar effect. Concomitant 
obstructive sleep apnea (OSA) affects 34%–61% of patients 
with RBD,11–13 and it is common for RBD to be diagnosed fol-
lowing an initial referral for suspected OSA.14 Given the link 
Statement of Significance
This is the largest study to date comparing the clinical characteristics of  rapid eye movement (REM) sleep behavior disorder (RBD) patients with 
Parkinson’s disease (PD) patients and healthy controls. Our data show that people with RBD have a nonmotor phenotype that is as severe as that seen 
in early PD, suggesting that they represent the prodromal phase of  a worse nonmotor disease subtype. We found that antidepressant use and obesity 
are common in RBD and associated with a lower probability of  hyposmia, perhaps indicating a lower near-term conversion risk. We have also evaluated 
the new Movement Disorder Society Research Criteria for Prodromal Parkinson’s and identified some important strengths and limitations. Longitudinal 
follow-up will determine the true predictive value of  these risk models.
Downloaded from https://academic.oup.com/sleep/article-abstract/40/8/zsx071/3796343
by University of Bristol Library user
on 08 December 2017
2SLEEP, Vol. 40, No. 8, 2017 RBD in prodromal alpha-synucleinopathies—Barber et al.
between body mass index (BMI) and sleep-disordered breath-
ing, we hypothesized that individuals with high BMI may also 
present at an earlier neurodegenerative stage.
Another factor that may contribute to regional variations 
among RBD cohorts is genetic risk. Recent evidence suggests 
that the genetic profile of RBD is not the same as for PD in 
general. Mutations in the leucine-rich repeat kinase 2 (LRRK2) 
gene are the most common cause of familial PD,15 but patients 
with LRRK2-associated PD have lower rates of RBD than seen 
in sporadic PD,16 and LRRK2 mutations were not detected in 
a large Spanish cohort of idiopathic RBD.17 Mutations in the 
glucocerebrosidase gene (GBA), on the other hand, appear to 
be associated with a more severe nonmotor phenotype in estab-
lished PD18,19 and have a high prevalence in idiopathic RBD.20 
The rates of such genetic risk factors show substantial variation 
among different ethnic groups,21 and these findings therefore 
require validation in geographically distinct populations.
Here, in the largest study of its kind to date, we comprehen-
sively assess the baseline clinical, genetic, and background 
characteristics of a UK cohort of 171 patients with idiopathic 
RBD, comparing them with 296 control participants and 119 
patients with early PD. We use these clinical characteristics to 
explore models that may stratify neurodegenerative risk.
METHODS
Subjects
Patients with idiopathic RBD were recruited from sleep disor-
ders clinics at three centers: John Radcliffe Hospital, Oxford; 
Papworth Hospital, Cambridge; and Sheffield Teaching 
Hospital. The diagnosis of RBD was made on the basis of 
polysomnographic (PSG) evidence according to International 
Classification of Sleep Disorders criteria.22 Individuals with 
concomitant OSA were only included if the two conditions 
were unequivocally distinguishable by PSG. In uncertain cases, 
the diagnosis of RBD was either confirmed by repeat PSG with 
the use of continuous positive airway pressure, or the individu-
als were excluded from the study.
Healthy controls and patients with PD (diagnosed according to 
UK PD Brain Bank Criteria23) were selected from the Discovery 
Cohort of the Oxford Parkinson’s Disease Centre, a community 
ascertained cohort recruited from the Thames Valley region. In 
order to avoid the potential confounding effects of antiparkin-
sonian medication and to establish a comparison with the PD 
population closest to the prodromal phase, we only included 
patients with early, untreated PD. Full details of our clinical 
protocol are described elsewhere.24 The study was approved by 
the local research ethics committee and informed, written con-
sent was given by all participants.
Subject Evaluation
A comprehensive, structured medical history was taken from 
all participants including comorbidities, demographic informa-
tion, environmental and occupational exposures, medications, 
and family history. Motor features were assessed using: part III 
of the MDS revised Unified Parkinson’s Disease Rating Scale 
(UPDRS25); the Purdue Pegboard test26; the Flamingo test (the 
ability of the patient to balance on one leg for 30 seconds), and 
the timed “get-up-and-go” test.24 Olfaction was assessed using 
the “Sniffin’ Sticks” odor identification test.27 Cognition was 
assessed using the Mini-Mental State Examination (MMSE28) 
and the Montreal Cognitive Assessment (MoCA29), with scores 
for the latter adjusted for years of education. Mild cognitive 
impairment was defined according to the MoCA diagnostic cutoff 
(<24/30).24 For phonemic fluency, the total number of words gen-
erated beginning with F, A, and S over 60 seconds was recorded. 
For semantic fluency, the number of animals and boys’ names 
each generated in 60 seconds was counted. Both fluency scores 
were adjusted for age. The Beck Depression Inventory (BDI-II30) 
and the Leeds Anxiety and Depression Scale (LADS31) were used 
to evaluate depression and anxiety respectively. Self-reported 
nonmotor symptoms were assessed using UPDRS part I. EQ-5D 
was used as a standardized self-report measure of health status.32 
Cardiovascular risk factors were defined as: history of cardiovas-
cular disease (angina, myocardial infarction, stroke, or transient 
ischemic attack); current smoker; hypertension; hypercholester-
olemia; obesity (BMI > 30 kg/m2); and diabetes.
Genetic Testing
Participants were screened for G2019S and R1441C mutations 
in the LRRK2 gene and N370S and L444P mutations in the GBA 
gene. For the LRRK2 screening, results were available for 289 
controls, 136 patients with RBD, and 114 patients with PD. For the 
GBA screening, results were available for 283 controls, 116 RBD, 
and 106 participants with PD. DNA was extracted from whole 
blood using a Qiagen Autopure automated system. Polymerase 
chain reaction (PCR) was performed using MegaMix Blue 
(Microzone) containing a recombinant Taq polymerase. Primer 
sequences were as follows: G2019S: 5′-TTTAAGGGACAAA 
GTGAGCAC-3′ and 5′-ACTCTGTTTTCCTTTTGACTC-3′; 
R1441C: 5′-AAGGCATGAAGATGGGAAAG-3′ and 5′-TGA 
TGGTTTTCCGAAGTTTTG-3′; N370S: 5′-GCCTTTGTCCTT 
ACCCTC*G-3′ and 5′-GACAAAGTTACGCACCCAA-3′; 
L444P: 5′-GGAGGACCCAATTGGGTGCGT-3′ and 5′-ACG 
CTGTCTTCAGCCCACTTC-3′ (* indicates a mismatch that 
was introduced into the forward primer to create a restriction 
site).The PCR products for G2019S, R1441C, N370S, and 
L444P were digested with SfcI (BfmI), BstUI, XhoI, and NciI 
(BcnI), respectively and resolved by agarose gel electrophoresis.
Statistical Analysis
Between-groups comparisons of clinical features were made 
using a linear regression model for continuous variables and 
a logistic regression model for dichotomous variables. As the 
groups were not precisely age and gender matched, we included 
age and gender as covariates in the model to control for any effect 
of these (except in the case of genetic data, where we included 
gender but not age). Statistical significance is presented as abso-
lute p values, uncorrected for multiple comparisons. Borderline 
p values should therefore be interpreted with caution due to the 
possibility of a type I error. A sensitivity analysis was performed 
excluding the 12 RBD participants who had uncorrected moder-
ate or severe OSA at the time of their diagnostic PSG.
Risk Stratification of RBD Versus Controls
We selected three risk factors that may help identify RBD cases 
where imminent phenoconversion to a neurodegenerative dis-
order is more likely. These were as follows: nonuse (high risk) 
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versus use (low risk) of antidepressants; presence (low risk) 
or absence (high risk) of obesity (BMI > 30kg/m2); and age 
above (high risk) versus below (low risk) 60 years. We then 
looked at the ability of these measures to predict the presence 
of hyposmia (Sniffin Sticks score < 10th centile adjusted for age 
and gender23), a surrogate marker of early neurodegeneration. 
Hyposmia was selected as the outcome because it is a com-
mon, early prodromal symptom (corresponding to stage 1 of 
the Braak hypothesis33) and, unlike motor or cognitive perfor-
mance, it is unlikely to be influenced by obesity or depression 
themselves. To compare how each risk factor modified the over-
all risk of hyposmia between RBD cases and controls, we ran a 
series of multivariable logistic regression models to derive the 
OR, with interaction terms for each risk factor and case status 
(RBD vs. control).
MDS Criteria for Prodromal PD
The probability of prodromal PD was calculated for each par-
ticipant at their baseline assessment using the method described 
by Berg et al.7 We used the following risk markers: sex, pesti-
cide exposure, solvent exposure, caffeine use, smoking history, 
family history of PD, and presence of gene mutation (GBA 
or LRRK2). The following prodromal markers were available 
for inclusion: RBD screening questionnaire (RBDSQ34), sub-
threshold parkinsonism (using UPDRS and Purdue Pegboard 
scores), olfactory loss, constipation, excessive daytime som-
nolence (measured by the Epworth Sleepiness Scale35), pos-
tural hypotension, urinary dysfunction, and depression/anxiety. 
PSG-proven RBD data were available for the RBD participants 
only, where it was used instead of the RBDSQ. The likelihood 
ratio for motor impairment was included in the calculation 
for all participants, including those with Parkinson’s. In cases 
where data were missing or ambiguous, a likelihood ratio of 1 
was used.
RESULTS
A total of 171 patients with idiopathic RBD (mean symptom 
duration 7.07 years, standard deviation [SD] 6.30), 296 healthy 
controls, and 119 participants with early, untreated PD (mean 
time since diagnosis 0.78 years, SD 0.78) were included in 
the study.
Demographics and Background Risk Factors
Key demographic, environmental, and genetic risk factors are 
shown in Table 1. Compared to controls, RBD participants 
had significantly higher rates of self-reported head injury and 
solvent exposure, both known risk factors for PD. Obesity and 
smoking were significantly more common in RBD participants 
than controls or patients with PD, and the total number of car-
diovascular risk factors was also higher in patients with RBD. 
The RBD group had a significantly higher rate of antidepressant 
use than controls or patients with PD and a significantly shorter 
duration of formal education.
Genetic Risk Variants
GBA mutations were detected in 3 out of 116 (2.6%) RBD par-
ticipants for whom DNA analysis was available, compared to 1 
out of 283 (0.4%) controls and 1 out of 106 (0.9%) PD. All GBA 
mutations detected were the N370S genotype. The difference in 
GBA mutation frequency between patients with RBD and con-
trols was of borderline significance (p = .05). None of the 136 
RBD or 289 control patients tested had either of the LRRK2 
mutations G2019S or R1441C. One out of 114 patients with PD 
tested had the G2019S mutation.
Early Motor Impairment in RBD
Table 2 summarizes the key motor and nonmotor features 
assessed in this study. Evidence of early motor impairment 
in RBD is demonstrated by significant differences between 
patients with RBD and controls in UPDRS-III scores, get-up-
and-go times, and successful completion of the flamingo task. 
Although the UPDRS-III scores in patients with RBD reflected 
an intermediate phenotype between controls and patients with 
PD, patients with RBD and PD were equally impaired on the 
Flamingo and get-up-and-go tasks. There was little difference 
on the Purdue Pegboard test between RBD and control partici-
pants, who both performed better than PD cases.
Nonmotor Parkinsonian Features in RBD
Patients with RBD showed impairment in a wide range of par-
kinsonian nonmotor characteristics (Table 2). They performed 
significantly worse than controls in the MMSE, MoCA, seman-
tic, and phonemic fluency tests, as well as in measures of olfac-
tion, constipation, and orthostatic hypotension. In all of these 
tests, RBD participants were at least as impaired as PD par-
ticipants. RBD participants were more likely to report symp-
toms of postural lightheadedness than either controls or people 
with PD.
Mood disorders were significantly worse in RBD participants 
than in controls or patients with PD. BDI and Leeds Anxiety 
Scale scores indicated a higher level of depression and anxiety 
in participants with RBD compared to controls or patients with 
PD, and participants with RBD were almost twice as likely as 
patients with PD to report apathy.
When asked to report their overall QOL using the EQ5D 
score, the reduction seen in RBD compared to control partici-
pants was as large as that seen in patients with established PD. 
Overall self-reporting of nonmotor symptoms in the UPDRS 
part I revealed significantly worse symptom scores in patients 
with RBD than in those with PD.
Table 3 shows the ORs for various parkinsonian features in 
patients with RBD compared to controls, adjusted for age and 
gender differences. As expected, patients with RBD showed 
increased ORs, varying from just over double (eg, cognitive 
impairment OR 2.04, 95% CI 1.19–3.49) to hyposmia which 
showed around a 14-fold relative odds (OR 13.8, 95% CI 
8.13–23.4).
The Effect of Antidepressants and Obesity
Within the group of patients with RBD, hyposmia was less 
severe in those taking antidepressant medication. Mean Sniffin 
Sticks score was 9.69 in those taking antidepressants compared 
to 7.36 in those not (p < .001). RBD participants taking anti-
depressants were also significantly younger (59.9 years vs. 
67.0 years, p < .001). Importantly, these differences were not 
seen in the control group when comparing those taking and 
not taking antidepressants (p = .63 and p = .39 for the differ-
ences in Sniffin Sticks scores and age, respectively). A formal 
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Table 1—Demographics and Background Risk Factors.
Demographic/background risk variable Controls
N = 296
RBD
N = 171
PD
N = 119
p value
Age, mean (SD) 64.9 (10.2) 64.7 (9.0) 66.9 (9.1) RBD versus control:
RBD versus PD:
PD versus control:
.79
.06
.06
Sex (% male) 49.0 88.3 70.6 RBD versus control:
RBD versus PD:
PD versus control:
 <.001
 <.001
 <.001
Body mass index (BMI)
Mean, kg/m2 (SD)
27.4 (4.93) 29.1 (5.91) 26.1 (3.73) RBD versus control:
RBD versus PD:
PD versus control:
.003
 <.001
.02
Pesticide exposure* (%) 37.2 43.9 33.9 RBD versus control:
RBD versus PD:
PD versus control:
.27
.10
.44
Solvent exposure+ (%) 11.1 22.2 18.6 RBD versus control:
RBD versus PD:
PD versus control:
.05
.93
.10
Caffeine intake** 4.71 (2.24) 5.39 (2.70) 5.00 (2.87) RBD versus control:
RBD versus PD:
PD versus control:
.08
.41
.47
Head injury++ (%) 18.2 32.2 22.9 RBD versus control:
RBD versus PD:
PD versus control:
.02
.24
.41
Smoking history*** (%) 43.2 63.2 40.2 RBD versus control:
RBD versus PD:
PD versus control:
.002
 <.001
.31
Obesity^ (%) 23.3 36.8 16.0 RBD versus control:
RBD versus PD:
PD versus control:
.002
 <.001
.16
Education (years) 15.1 (3.45) 13.7 (3.39) 15.1 (3.86) RBD versus control:
RBD versus PD:
PD versus control:
 <.001
 <.001
.64
Antidepressant use (%) 11.5 32.2 12.6 RBD versus control:
RBD versus PD:
PD versus control:
 <.001
 <.001
.25
GBA mutation^^ (%) 0.40 2.6 0.90 RBD versus control:
RBD versus PD:
PD versus control:
.05
.31
.40
LRRK2 mutation^^ (%) 0 0 0.90 RBD versus control:
RBD versus PD:
PD versus control:
n/a
1.0
.99
Total number of  cardiovascular risk factors, 
mean (SD)+++
1.01 (1.11) 1.55 (1.44) 1.08 (1.14) RBD versus control:
RBD versus PD:
PD versus control:
 <.001
 <.001
.98
RBD participants have higher rates of  chemical solvent exposure, head injury, smoking, obesity, and antidepressant use than controls. Shorter educational 
experience and higher total number of  cardiovascular risk factors are also associated with RBD.
*Exposure to pesticides at work or home; +exposure to chemical solvents for  > 6 months; **past caffeine intake: number of  caffeinated drinks per day; 
++history of  head injury causing loss of  consciousness or concussion diagnosed by a doctor; ***past or current smoking history; ^BMI  > 30 kg/m2; +++risk 
factors defined as: history of  cardiovascular disease (angina, myocardial infarction, stroke or transient ischaemic attack), diabetes, obesity, hypertension, 
current smoker, hypercholesterolaemia. For all variables except age, sex and GBA/LRRK2 status, p values for between groups comparisons are corrected 
for age and sex. The comparison of  GBA/LRRK2 status is adjusted for sex only. ^^for the numbers of  patients tested for genetic mutations, see main text. 
GBA = glucocerebrosidase; LRRK2 = leucine-rich repeat kinase 2; RBD = rapid eye movement sleep behavior disorder; PD Parkinson’s disease; 
SD = standard deviation.
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Table 2—Motor and Nonmotor Features.
Clinical variable Controls
N = 296
RBD
N = 171
PD
N = 119
Significance
(p values)
Non-motor Values are mean (SD) unless otherwise stated
UPDRS III, score 1.74 (2.74) 4.79 (5.97) 25.7 (11.1) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
 <.001
 <.001
Purdue Pegboard, score 37.5 (6.80) 36.8 (8.04) 28.6 (6.49) RBD versus controls:
RBD versus PD:
PD versus controls:
.69
 <.001
 <.001
Flamingo, % 71.0 53.9 55.3 RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.13
.002
Get up and go, time (seconds) 8.51 (1.73) 9.49 (3.17) 9.56 (2.24) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.67
 <.001
Nonmotor
MMSE, score 28.3 (1.89) 27.3 (2.10) 27.6 (2.29) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.13
.002
MoCA, score 26.7 (2.67) 25.1 (2.92) 25.2 (3.32) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.64
 <.001
Mild cognitive impairment (MoCA  < 24) % 12.5 24.7 27.6 RBD versus versus controls:
RBD versus PD:
PD versus controls:
.01
.57
.003
Semantic fluency, score 12.0 (3.33) 9.78 (3.35) 10.5 (3.34) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.12
 <.001
Phonemic fluency, score 12.8 (3.72) 10.4 (4.00) 11.5 (4.01) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.04
.004
Sniffin’ sticks, score 12.1 (2.28) 8.13 (3.26) 7.46 (2.88) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.06
 <.001
Orthostatic systolic blood pressure drop, mmHg 0.09 (12.3) 5.33 (13.6) 3.75 (13.5) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.27
.03
Postural lightheadedness % 12.2* 42.3 27.1 RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.01
.005
Constipation, % 34.7 47.3 39.8 RBD versus controls:
RBD versus PD:
PD versus controls:
.002
.08
.34
Beck Depression Inventory Score 4.85 (5.02) 10.25 (9.59) 7.55 (5.88) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.001
 <.001
Leeds Anxiety Score 2.12 (2.38) 4.29 (3.84) 2.77 (2.98) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
 <.001
.007
Apathy (UPDRS part I, %  > 0) Not measured 29.8 16.2 RBD versus PD .02
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interaction test between patient group and antidepressant use 
revealed strong evidence of an interaction for both Sniffin 
Sticks (p < .001) and age (p = .022).
A similar effect on olfaction was seen relating to BMI. 
Patients with RBD who were not obese (BMI < 30 kg/m2) 
had significantly worse Sniffin Sticks scores (7.48 vs. 9.18, 
p = .001) than obese RBD participants. This effect was not 
seen in the control group (nonobese vs. obese Sniffin scores 
12.0 vs. 12.1, p = .99), and a strong interaction was present 
between patient group and BMI for the Sniffin Sticks outcome 
(p = .003), suggesting that the effect of BMI on olfaction is 
specific to RBD.
The combination of participant status for obesity, antide-
pressant use, and age conferred an additive effect on the risk 
of impaired olfaction. Table 4 presents the ORs for hyposmia 
comparing patients with RBD with controls depending on the 
presence or absence of antidepressant use, obesity, and age. In 
patients with RBD, considered low risk for all three variables, 
the difference in risk compared to controls was consistent with 
chance (OR 3.39, 95% CI 0.78–14.8). Patients with RBD in the 
high risk category for all three variables had markedly increased 
risk (OR 45.5, 95% CI 21.1–98.0, p < .001).
MDS Criteria for Prodromal Parkinson’s
Table 5 shows the probability of prodromal PD for the control, 
RBD, and early PD groups. Median values of absolute probabil-
ity were 92.8% for patients with RBD, 0.48% for controls, and 
52.2% for patients with early PD. Using the suggested MDS 
cutoff of more than 80% for a diagnosis of probable prodromal 
PD, around 74% (95% CI 66%–80%) of people with RBD ful-
filled the criteria compared to 0.3% (95% CI 0.009%–2%) of 
controls and 21.8% (95% CI 14.8%–30.4%) of patients with 
early PD. With a lower threshold of more than 50%, 92.4% 
(95% CI 87.4%–95.6%) of patients with RBD met criteria 
compared to 1.4% (95% CI 0.4%–3.4%) of controls and 51.3% 
(95% CI 41.9%–60.5%) of patients with early PD.
Significant Comorbid OSA
Twelve of the RBD participants had more than mild OSA that 
was uncorrected at PSG; by apnea-hypopnea index (AHI) 
this was classed as moderate (AHI 15–30) in 11 cases and 
severe (AHI  > 30) in one. The analyses presented in Tables 
1–5 were repeated with these 12 participants excluded and 
the results are presented in Supplementary Tables S1–S5. 
Excluding these participants had no significant effect on the 
results of the analysis. The median probability of prodromal 
Parkinson’s in the 12 participants with significant comorbid 
OSA was 99.0%.
Conversion to Defined Neurodegenerative Disease
The mean duration of follow-up for the RBD cohort at the time 
of writing is 2.1 years (SD 1.25). Of the 171 patients with RBD 
recruited to the study, 16 have subsequently been diagnosed 
Table 3—Increased Risk of  Parkinsonian Features in RBD Versus 
Controls.
Clinical feature RBD versus controls 
adjusted for age and gender 
Odds ratio (95% CI)
Motor impairment^ 6.46 (3.64–11.5)
Cognitive impairment* 2.04 (1.19–3.49)
Hyposmia** 13.8 (8.13–23.4)
Depression*** 6.93 (3.54–13.5)
Anxiety+ 6.45 (3.06–13.6)
Constipation++ 2.07 (1.34–3.21)
Orthostatic hypotension+++ 4.34 (2.12–8.88)
Patients with RBD have greatly increased risk of  Parkinsonian features 
compared to controls.
^Unified Parkinson’s Disease Rating Scale (UPDRS) part III, score  > 4; 
*Montreal Cognitive Assessment (MoCA)  < 24; **Sniffin’ Sticks 
score  < 10; ***Beck Depression Inventory score  > 13; +Leeds Anxiety 
Score  > 6; ++less than one bowel movement per day or use of  laxatives; 
+++Orthostatic drop in systolic blood pressure  > 20 mmHg.
CI = confidence interval; RBD = rapid eye movement sleep behavior disorder.
Clinical variable Controls
N = 296
RBD
N = 171
PD
N = 119
Significance
(p values)
Non-motor Values are mean (SD) unless otherwise stated
Quality of  life
EQ5D % score
84.5 (10.6) 74.0 (19.7) 76.0 (14.4) RBD versus controls:
RBD versus PD:
PD versus controls:
 <.001
.28
 <.001
UPDRS I, total score Not 
measured
9.49 (6.45) 6.95 (4.53) RBD versus PD  <.001
Patients with RBD are impaired in a wide range of  motor and nonmotor characteristics compared to controls. In all measures except UPDRS III and Purdue 
Pegboard, participants with RBD are at least as impaired as those with early PD. In measures of  depression, anxiety, apathy, phonemic fluency, and postural 
lightheadedness, people with RBD scored significantly worse than participants with PD.
All p values for two-way comparisons are corrected for age and gender differences between the groups. 
*Data regarding this symptom was only available from 114 controls.
MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment; PD = Parkinson’s disease; RBD = rapid eye movement sleep behavior 
disorder; SD = standard deviation; UPDRS = Unified Parkinson’s Disease Rating Scale.
Table 2—Continued
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with a defined neurodegenerative disorder. The diagnosis was 
PD in nine participants; DLB in one; MSA in two; dementia 
without parkinsonism in three participants, and pure autonomic 
failure in one. Neurodegenerative diagnoses were made after 
a mean latency of 5.6 years (SD 2.45) from PSG confirmation 
of RBD and 9.8 years (SD 3.17) from RBD symptom onset. 
Three of the patients who converted to a neurodegenerative dis-
order had concomitant moderate OSA (AHI 15–30). Of the 10 
patients who converted to PD or DLB, eight met the MDS crite-
ria for probable prodromal Parkinson’s at baseline.
DISCUSSION
In the largest study to date comparing the clinical phenotype 
of patients with RBD to that of patients with PD and healthy 
controls, we have demonstrated evidence of motor, autonomic, 
mood, and cognitive impairment in patients with RBD. In 
every nonmotor feature, participants with RBD are at least as 
impaired as patients with early PD, and in measures of depres-
sion, anxiety, and apathy, patients with RBD score worse than 
those with established Parkinson’s. This may explain the finding 
that patients with RBD rate their QOL as low as patients with 
early PD. We have previously shown that in patients with estab-
lished PD, the presence of RBD is associated with lower QOL.36 
Our data suggest that this effect appears during the prodromal 
phase and highlight the importance of recognizing and actively 
managing nonmotor symptoms.
The fact that patients with RBD do not exhibit an intermedi-
ate nonmotor phenotype between controls and patients with PD 
is in keeping with evidence that patients with PD who progress 
from idiopathic RBD tend to develop the akinetic-rigid/postural 
instability-gait difficulty subtype of disease,1 which is associ-
ated with a more severe nonmotor phenotype.37 This may also 
explain why our RBD and early patients with PD are equally 
impaired on the flamingo test (a measure of postural instability) 
and the get-up-and-go test (a measure of gait) despite patients 
with RBD having substantially lower UPDRS III scores.
Among demographic and environmental variables, we found 
that smoking and history of head injury were more common in 
patients with RBD than controls and duration of formal educa-
tion was shorter, replicating the findings of a large multicentre 
study of risk factors for RBD.38 We also found that exposure 
to chemical solvents, but not pesticides, was more common in 
RBD and that the total number of cardiovascular risk factors 
was higher compared to controls. The findings with respect 
to head injury and solvent exposure are consistent with their 
known status as risk factors for Parkinson’s. The higher preva-
lence of smoking on the other hand is in conflict with the pro-
tective effect observed in relation to PD. The explanation for 
Table 4—RBD Patient Stratification and Risk of  Hyposmia.
Not on antidepressants BMI < 30 Age > 60 Odds ratio (95% CI) for hyposmia*, RBD versus 
control
No No No 3.39 (0.78, 14.8)
Yes No No 5.63 (1.57, 20.2)
No No Yes 7.42 (1.91, 28.8)
Yes No Yes 12.3 (4.45, 34.0)
No Yes No 12.5 (2.62, 60.0)
Yes Yes No 20.8 (6.79, 63.8)
No Yes Yes 27.4 (6.56, 114.6)
Yes Yes Yes 45.5 (21.1, 98.0)
The odds ratio for hyposmia in RBD compared to controls increases more than 13-fold following risk stratification.
*Hyposmia defined as Sniffin Sticks score  < 10th centile of  normative data adjusted for age and gender. 
BMI = body mass index; CI = confidence interval; RBD = rapid eye movement sleep behavior disorder.
Table 5—MDS Criteria for Prodromal Parkinson’s at Baseline According to PD, RBD, or Control Status and for RBD Converters to PD/DLB.
Probability value/threshold Controls
n = 296
RBD
N = 171
PD
N = 119
Converted from RBD to PD or DLB at follow-up
(N = 10)
Observed median probability of  prodromal PD 0.48% 92.8% 52.2% 96.3%
 > 80% probability 0.3% 73.7% 21.8% 80.0%
 > 50% probability 1.40% 92.4% 51.3% 100%
Participants with RBD have a high probability of  prodromal Parkinson’s according to MDS criteria. Only 0.3% of  control participants fulfilled criteria using the 
suggested 80% cutoff. All the RBD participants who converted to PD had probability >50% at baseline.
All values are at baseline evaluation.
DLB = dementia with Lewy bodies; MDS = Movement Disorder Society; PD = Parkinson’s disease; RBD = rapid eye movement sleep behavior disorder.
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this is not clear; it remains uncertain whether there is indeed a 
real effect of smoking and vascular risk on the development of 
RBD or whether these differences are a result of selection bias 
in RBD cohorts.
Our findings support recent studies of the association 
between RBD and mutations in the LRRK2 and GBA genes. 
Taking our data alongside the only other published study of 
LRRK2 in idiopathic RBD,17 no mutations have been found in 
a combined total of 261 patients with RBD, substantially less 
than the prevalence of around 3% seen in sporadic PD.39 This 
provides further evidence that LRRK2-PD is associated with a 
lower incidence of RBD in the prodromal phase of the disease. 
In contrast, we found a higher prevalence of two common GBA 
mutations in RBD compared with controls. Although this result 
was of borderline statistical significance, it is in keeping with 
recent evidence linking GBA mutations with RBD in both PD 
and non-PD GBA carriers.18,20,40
We have shown that in patients with idiopathic RBD, lower 
BMI is associated with worse hyposmia, a common feature of 
prodromal PD corresponding to stage 1 of the Braak pathological 
staging system.33 Importantly, this difference is not seen in the 
control group, suggesting that the effect of BMI is specifically 
related to RBD. One possible explanation for this is the associa-
tion between higher BMI and respiratory sleep disorders. OSA is 
a common condition that frequently coexists with RBD,11–13 and 
it is not uncommon for patients to be diagnosed with RBD fol-
lowing presentation to the sleep clinic with suspected OSA.14 We 
suggest that the presence of even mild OSA or other sleep-disor-
dered breathing may prompt earlier referral to a sleep center and 
consequent diagnosis of RBD at an earlier prodromal stage than 
in those with RBD alone. Bias toward the referral of obese indi-
viduals may also underlie the significantly higher rate of obesity 
observed between RBD and control participants.
A similar effect is seen with antidepressant medications, 
use of which has been reported elsewhere as associated with 
a substantially reduced risk of conversion from RBD to neu-
rodegenerative disease.6 Antidepressants are known to exacer-
bate RBD,10 and their use may therefore also lead to earlier PSG 
examination. In keeping with this hypothesis, patients with 
RBD taking antidepressants are younger and have less hypos-
mia and orthostatic hypotension than those not taking antide-
pressants, an effect that is not seen in the control group.
Combining these factors with age, we demonstrate that 
patients with RBD considered low risk in all three measures 
have an OR of 3.39 (95% CI 0.78–14.8) compared to con-
trols for impaired olfaction, a difference that is consistent with 
chance. In those considered high risk in all three categories, 
the OR is 45.5 (95% CI 21.1–98). Longitudinal follow-up will 
establish whether these “high-risk” patients are more likely to 
convert to a neurodegenerative disorder, but the differences are 
striking and suggest that simple demographic data can contrib-
ute significantly to risk stratification.
The finding that 73.7% of patients with RBD fulfil the MDS 
criteria for probable prodromal PD is in line with longitudinal 
studies demonstrating a similar rate of conversion to neurode-
generative disease.6 However, this figure is largely accounted 
for by the PSG diagnosis of RBD itself, as excluding the likeli-
hood ratio relating to this and using the RBDSQ instead would 
result in just 12% of patients with RBD fulfilling the criteria. 
Although this reflects the importance of PSG-confirmed RBD 
as a prodromal marker, it also highlights the reliance of these 
criteria on specialist investigations in order to obtain high sen-
sitivity. This is further illustrated by the result in our early PD 
cohort, where patients did not undergo PSG or other invasive 
investigations. Using simple clinical measures only, just 21.3% 
of these patients met the criteria (NB although these patients 
by definition are not prodromal, the diagnosis of PD is recent 
[median time since diagnosis 0.56 years], and the risk factors 
incorporated in the MDS criteria will not reduce with time, so 
one can assume that probability scores would have been the 
same or lower in the prodromal phase). If, on the other hand, all 
these patients had had positive neuroimaging with DAT SPECT, 
the sensitivity of the MDS criteria would improve to 87%.
The low number of control participants fulfilling the criteria 
(0.3%) makes this a potentially useful tool for recruitment of pro-
dromal patients to clinical trials, where a low false-positive rate may 
take precedence over high sensitivity. The sensitivity of the criteria 
could be increased by using a threshold of 50% instead of 80%, as 
others have suggested.8 In this instance, 98.6% of our healthy con-
trols would still fall below the threshold, but 51.3% of patients with 
early PD would now meet criteria using simple clinical measures 
alone and 92.4% of participants with RBD. Importantly, 100% of 
the patients with RBD in our cohort who converted to PD or DLB 
would have met the 50% threshold at baseline.
Some limitations of this study should be noted. Interpretation 
of the demographic differences is somewhat limited by the fact 
that the RBD cohort was recruited from sleep centers throughout 
the United Kingdom, whereas the PD and control participants 
were recruited only from the Thames Valley region. Although our 
findings are consistent with two other large studies evaluating 
environmental risk factors for RBD,38,41 it is possible that in our 
study the differences simply reflect confounding by geographical 
variation. The large number of participants included in this study 
meant that it was not feasible to undertake PSG on the control 
or participants with PD. However, the primary comparison was 
between RBD and controls, and RBD is rare in the general popu-
lation. If a small number of patients with RBD were inadvertently 
present in the control group, the effect would be small and would 
be likely to reduce the differences observed between RBD and 
control participants rather than exaggerate them.
In conclusion, our study has demonstrated extensive evidence of 
neurodegeneration in a large RBD cohort that is in keeping with 
the prodromal phase of alpha-synucleinopathies. Our data suggest 
that simple clinical measures can be used to risk stratify these 
patients, though this requires further replication. Longitudinal fol-
low-up is underway and will establsh the true predictive value of 
these methods. Work to further refine the stratification model with 
novel neuroimaging and molecular tests is ongoing in our group. 
These tests will be important in selecting those at highest risk of 
conversion so that outcomes can be assessed within a time scale 
feasible for clinical trials of neuroprotective agents.
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